Glaukos Corp Stock
€92.50
Your prediction
Financial data and news for Glaukos
sharewise wants to provide you with the best news and tools for Glaukos, so we directly link to the best financial data sources.
Financials
News
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off
Baltimore-based Brown Capital Management reported a sale of 376,359 Glaukos Corporation shares for an estimated $34.6 million in the third quarter, according to an SEC filing.
Brown Capital
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday
Glaukos (NYSE: GKOS), a biotech and pharmaceutical company focused on eye disorders, was the focus of the right kind of investor attention on Thursday. Market players bid the company's stock up by
Glaukos (GKOS) Q2 Revenue Jumps 30%
Glaukos (NYSE:GKOS), a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of


